BIO Double Helix Sponsor
Sponsors

Company Profile

SensiGen, LLC

Molecular Diagnostics
Infectious Diseases
Renal

2900 Huron Parkway, suite 1146
Ann Arbor, MI 48105
USA
www.sensigen.com 		Incorporated in 2003
9 Employees 		Privately Held

This Year's Highlights

  • Announced exclusive world-wide license and marketing alliance with Sequenom (NASDAQ: SQNM) for distribution of proprietary systems and molecular reagent test kits for Human Papilloma Virus (HPV), Nephrin (chronic kidney disease), Lupus, and IBD.
  • Completed clinical plan for lead product -- a quanitiative, genotype-specific, 16-plex screening assay for HPV sensitive down to a single copy of pathogenic DNA in a biological sample.
  • Completed first ever quanitative assay for Nephrin in urine -- an early detection and treatment monitoring test for chronic kidney disease.

Anticipated Highlights

  • Completion of intial round of institutional financing ("Series A") anticipated November 2007.
  • Commencement of HPV clinical trials Q1 2008.
  • Publication of Nephrin data -- first ever early detection and treatment monitoring tool for chronic kidney disease (afflicting 20M people in the US).

Corporate Mission

SensiGen is a development stage biotechnology company focused on gene-based molecular diagnostics. It develops advanced technologies enabling early detection of diseases, thereby improving the standard of care and reducing overall health costs. To date, SensiGen?s technology platform has been applied to the development of proprietary diagnostic tests for human papilloma virus (HPV), the primary cause of cervical cancer, to chronic kidney disease (CKD), a serious condition associated with diabetes, hypertension, and lupus, and to IBD and Lupus. These proprietary diagnostic assays offer dramatic improvements over current methods.